Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD

Treatment of NAFLD with diet, physical activity and exercise

(2017) Manuel Romero-Gómez et al.   JOURNAL OF HEPATOLOGY

Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years

(2017) Alessandro Federico et al.   MOLECULES

Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver

(2017) Federico Salomone et al.   Nutrients

Experimental studies on soft contact lenses for controlled ocular delivery of pirfinedone: in vitro and in vivo

(2016) Mei Yang et al.   DRUG DELIVERY

Anti-Obese Effect of Glucosamine and Chitosan Oligosaccharide in High-Fat Diet-Induced Obese Rats

(2015) Lanlan Huang et al.   Marine Drugs

Serum TAG Analysis Differentiates Between Genetic and Obesity-Associated NAFLD

(2013) D. G. Mashek et al.   DIABETES

Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway

(2013) Yongxiang Zhang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: In vitro and in vivo evaluation

(2013) Chao Feng et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Evaluation of Ultrasound Combined with Chitosan for the Control of Weight and Local Fat in Mice

(2013) Ai-Ho Liao et al.   ULTRASOUND IN MEDICINE AND BIOLOGY

Single-Step Assembly of Cationic Lipid–Polymer Hybrid Nanoparticles for Systemic Delivery of siRNA

(2012) Xian-Zhu Yang et al.   ACS Nano

Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis

(2012) John Zhong Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis

(2012) Federico Salamone et al.   Translational Research

Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease

(2012) Yu-Yuan Li   WORLD JOURNAL OF GASTROENTEROLOGY

Factors affecting drug encapsulation and stability of lipid–polymer hybrid nanoparticles

(2011) Wean Sin Cheow et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Synthesis of Carboxymethylated and Quaternized Chitosans and Their Therapeutic Effect on Nonalcoholic Fatty Liver Disease

(2011) Xiaofei Liu et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies

(2011) Tore-Geir Iversen et al.   Nano Today

Advances in using chitosan-based nanoparticles forin vitroandin vivodrug and gene delivery

(2010) Nicolas Duceppe et al.   Expert Opinion on Drug Delivery

I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease

(2010) Luca Valenti et al.   HEPATOLOGY

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

(2010) Yaron Rotman et al.   HEPATOLOGY

Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition

(2010) Guixia Ling et al.   JOURNAL OF CONTROLLED RELEASE

The formation of lipid bilayers on surfaces

(2009) Sandra Gromelski et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans

(2009) A. Kotronen et al.   DIABETOLOGIA

Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles

(2009) Hae Yun Nam et al.   JOURNAL OF CONTROLLED RELEASE

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

(2008) Stefano Romeo et al.   NATURE GENETICS